Alyeska Investment Group
RCKT icon

Alyeska Investment Group’s Rocket Pharmaceuticals RCKT Stock Holding History

Alyeska Investment Group’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-30,312
Closed -$202K – 651
2025
Q1 		$202K Hold
30,312
– – ﹤0.01% 489
2024
Q4 		$381K Buy
+30,312
New +$456K ﹤0.01% 524

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Alyeska Investment Group's RCKT Position: Q2 2025 in Review

Alyeska Investment Group sold out of Rocket Pharmaceuticals (RCKT) in Q2 2025, closing a stake of 30,312 shares — an estimated $202K sold.

Alyeska Investment Group first reported a position in RCKT in Q4 2024 and held it in 2 quarters. The position peaked at $381K in Q4 2024. 196 funds tracked by Wall St. Rank hold RCKT as of Q2 2025.

  • Alyeska Investment Group reported no remaining Rocket Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Alyeska Investment Group sold 30,312 Rocket Pharmaceuticals shares in Q2 2025, an estimated $202K.
  • Alyeska Investment Group first reported a position in Rocket Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Alyeska Investment Group's Rocket Pharmaceuticals position peaked at $381K in Q4 2024.
  • 196 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2025.

Based on Alyeska Investment Group's 13F filing for Q2 2025, filed 14 Aug 2025.